Screener
Rigel Pharmaceuticals RIGL Capitalized research and development expenses
Capitalized research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses.
The source filing: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026.
- Filed
- Mar 3, 2026, 4:06 PM EST
- Fiscal year
- FY2025
- Accession
- 0001034842-26-000015
| Line item | As of December 31, 2025 | As of December 31, 2024 |
|---|---|---|
| Deferred tax assets | ||
| Net operating loss carryforwards | $216,008 | $222,744 |
| Orphan drug and research and development credits | 63,458 | 62,314 |
| Capitalized research and development expenses | 5,165 | 19,604 |
| Deferred revenue | 334 | 10,181 |
| Deferred compensation | 4,616 | 11,701 |
| Other, net | 3,296 | 2,751 |
| Deferred tax liabilities |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Rigel Pharmaceuticals's capitalized research and development expenses?
- Rigel Pharmaceuticals (RIGL) reported capitalized research and development expenses of $5.17M in Q4 2025.
- What does capitalized research and development expenses mean?
- This metric reflects research and development expenditures that have been capitalized for tax purposes rather than expensed immediately, creating a deferred tax asset. It represents the tax benefit the company expects to realize in future periods as these costs are amortized or deducted. This figure is critical for understanding the company's tax strategy and the timing of its tax-related cash flows.
Ask your AI about Rigel Pharmaceuticals's capitalized research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude